Accepted for Publication: October 5, 2021.
Published Online: January 13, 2022. doi:10.1001/jamaoncol.2021.6597
Corresponding Author: Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215 (sara_tolaney@dfci.harvard.edu).
Author Contributions: Dr Tarantino had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Tarantino, Curigliano, Parsons, Krop, Winer, Tolaney.
Acquisition, analysis, or interpretation of data: Tarantino, Curigliano, Lin, Mittendorf, Waks, Tolaney.
Drafting of the manuscript: Tarantino, Curigliano, Mittendorf, Tolaney.
Critical revision of the manuscript for important intellectual content: All authors.
Administrative, technical, or material support: Tarantino, Curigliano, Tolaney.
Supervision: Tarantino, Curigliano, Parsons, Krop, Tolaney.
Conflict of Interest Disclosures: Dr Tarantino has served as an adviser/consultant to AstraZeneca and is supported by an American-Italian Cancer Foundation Post-Doctoral Research Fellowship. Dr Curigliano received honoraria for speaker, consultancy, or advisory roles from Roche, Pfizer, Novartis, Seattle Genetics, Lilly, Ellipses Pharma, Foundation Medicine, Daiichi Sankyo, and Samsung. Dr Parsons is a paid consultant for Foundation Medicine. Dr Lin reports research support (to institution) from Genentech, Merck, Pfizer, and Seattle Genetics; consultant/advisory board: Puma, Seattle Genetics, Daiichi Sankyo, AstraZeneca, Denali Therapeutics, California Institute for Regenerative Medicine, and Prelude Therapeutics. Dr Krop reports research support (to institution) from Genentech/Roche and Pfizer, has received fees from Novartis and Merck for Data Monitoring Board participation, received honoraria from Celltrion, and has received consulting fees from Bristol Myers Squibb, Daiichi/Sankyo, Macrogenics, Context Therapeutics, Taiho Oncology, Genentech/Roche, Seattle Genetics, and AstraZeneca. Dr Mittendorf has received research support from GlaxoSmithKline; honoraria from Physician Education Resource; compensation for serving on advisory boards for AstraZeneca, Exact Sciences, Merck, Peregrine Pharmaceuticals, Roche/Genentech, Sellas Lifesciences, and TapImmune; institutional support from AstraZeneca, EMD Serono, Galena Biopharma, and Roche/Genentech; and has served as an uncompensated steering committee member for Bristol Myers Squibb, Lilly and Roche/Genentech. Dr Waks receives institutional research funding from Genentech/Roche. Dr Winer is a scientific advisory board member for Leap, and reports consultancy fees from Garrick Therapeutics, G1 Therapeutics, Roche Genentech, Genomic Health, GlaxoSmithKline, Jounce, Lilly, Novartis, Seattle Genetics, and Syros, outside the submitted work. Dr Tolaney receives institutional research funding from AstraZeneca, Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics/Gilead, Exelixis, Bristol Myers Squibb, Eisai, Nanostring, Cyclacel, Odonate, and Seattle Genetics; has served as an adviser/consultant to AstraZeneca, Eli Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics/Gilead, Bristol Myers Squibb, Eisai, Nanostring, Puma, Sanofi, Puma, Silverback Therapeutics, G1 Therapeutics, Athenex, OncoPep, Kyowa Kirin Pharmaceuticals, Daiichi-Sankyo, Ellipsis, Infinity, 4D Pharma, Samsung Bioepsis, Inc, Chugai Pharmaceuticals, BeyondSpring Pharmaceuticals, OncXerna, OncoSec Medical Incorporated, Certara, Mersana Therapeutics, CytomX, Seattle Genetics.
Additional Contributions: We thank Kate Bifolck, BA, for her editorial and submission assistance (full-time employee of Dana-Farber Cancer Institute).